Intarcia Therapeutics has garnered $50 million to support the development of its lead therapeutic candidates for the treatment of hepatitis C and type 2 diabetes. New Leaf Venture Partners, a new investor, led the round with participation by Quilvest Ventures, also a new investor, and existing investors including New Enterprise Associates, Venrock Associates, Alta Partners, Omega Fund and Granite Global Ventures.
- see the release on the round
ALSO: Seattle-based Spaltudaq has raised $29 million in its second round. Report
PLUS: Life Sciences Partners III, BiomedInvest and Novartis Venture Fund have today announced the closing of a €7.2 million Series A round of Okairos, a newly established bio-pharmaceutical company in Basel, Switzerland. Release